Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment Group (AbHTAG):

Shyangdan D, Cummins E, Lois N, et al. Dexamethasone implants in the treatment of macular oedema due to retinal vein occlusion: a single technology appraisal. December 2010

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Allergan Ltd UK

II Professional/specialist and patient/carer groups:

  • Royal National Institute of Blind People (RNIB)

  • Royal College of Nursing

  • Royal College of Ophthalmologists

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • Welsh Assembly Government

  • Waltham Forest PCT

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Bristol Myers Squibb (triamcinolone)

  • Roche Products (bevacizumab)

  • Aberdeen HTA Group

  • National Institute for Health Research Health Technology Assessment Programme

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion by attending the initial Committee discussion and providing written evidence to the Committee. They are invited to comment on the ACD.

  • Ian Pearce, Consultant Ophthalmologist, nominated by The Royal College of Ophthalmologists – clinical specialist

  • Lady Sandra Taylor, Lead Ophthalomologist research Nurse Manager, nominated by Royal College of Nurses Ophthalmic Nurse Forum – clinical specialist

  • Barbara McLaughlan, Campaigns Manager, nominated by Royal National Institute of Blind people – patient expert

  • Carol Read, nominated by Royal National Institute of Blind people – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Allergan Ltd UK

  • National Institute for Health and Care Excellence (NICE)